Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III TAS-118 vs S-1 in gemcitabine-refractory advanced pancreatic cancer
jRCT2080222126Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of S-1 + leucovorin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Jun 2013; status: completed.
02
Drugs
S-1 + leucovorin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080222126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222126.